Inventiva S.A. (IVA)
$2.87-8.01%Close
SELLCRISIS · day 24
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $149M
- Beta
- 0.91
- P/E (TTM)
- -4.99
- Short % float
- 18.98%
- Days to cover
- 3.3
- SI change
- +72.0%
- 1W
- -17.05%
- 1M
- -26.03%
- vs SPY 1W
- -16.91%
- vs SPY 1M
- -28.54%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 1
- GROWTH
- 0
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-
REV YoY-
ROE-
EPS YoY-
ROA-98.6%
GROSS-5233
OP-306727
NET-505557
[VALUATION]
P/E TTM-4.99
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B12.26
P/FCF-
EV/EBITDA-14.07
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E112.98
ALTMAN Z-
CURR RATIO3.81
ND/EBITDA-
BETA0.91
Company news
FAQ
- What is LOPJLB’s current signal on IVA?
- LOPJLB’s latest quantitative signal on Inventiva S.A. (IVA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is IVA in?
- Inventiva S.A. (IVA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Inventiva S.A. (IVA) do?
- Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifi…